​​​​​​​Aimabs pursues two partnership pathways designed to create mutual value and expand global patient access:

Inbound Partnerships (Greater China Rights)

Aimabs partners with U.S. and global biotechs to secure exclusive Greater China (Mainland China, Hong Kong, Macau, Taiwan) development and commercialization rights for innovative therapies. We manage the full local lifecycle—regulatory strategy, clinical execution, and commercialization—while partners retain ownership and focus on global expansion.

Outbound Partnerships (Global/Western Rights)

Aimabs partners with China-based biotechs to prepare early-stage assets for global out-licensing to U.S./EU pharmaceutical partners. We help strengthen clinical strategy, regulatory readiness, and partnering positioning to maximize global value.

​​​​​​​For U.S./Global Biotechs

• Navigate regulatory complexity with integrated FDA/NMPA expertise

• Reduce operational burden through proven Greater China infrastructure

• Drive strong execution in high-growth specialty markets

​​​​​​​For China-Based Biotechs

• Align programs to global development and regulatory expectations early

• Access experienced cross-border teams to strengthen licensing readiness

• Accelerate global partnering and value creation for early-stage assets